AstraZeneca
-
FDA Approval of RSV Drug Gives Infants and Toddlers Long-Lasting Protection
AstraZeneca and Sanofi drug Beyfortus is now FDA approved for preventing respiratory problems from RSV infection in infants and toddlers. Antibody engineering enables the drug to last longer in the body, providing protective effects for potentially the entire RSV season.
-
AstraZeneca, Daiichi Cancer Drug’s Phase 3 Results Clouded by Toxicity Concerns
An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies disclosed few details about them.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
AstraZeneca Teams Up With Startup Quell in Type 1 Diabetes, IBD Cell Therapy Pact
AstraZeneca is paying $85 million to kick off an alliance with Quell Therapeutics focused on developing new cell therapies for autoimmune diseases. Type 1 diabetes and inflammatory bowel disease are the focus of the research collaboration.
-
Sanofi, AstraZeneca RSV Drug for Infants Secures Backing of FDA Advisors
An FDA advisory committee voted in favor of supporting a respiratory syncytial virus therapy designed to protect newborns and infants. The antibody drug developed by partners Sanofi and AstraZeneca is currently under regulatory review.
-
AstraZeneca, Daiichi Drug Shows Signs It Could Treat a Wide Range of Tumor Types
The HER2 protein targeted by the approved cancer drug Enhertu is found on a wide range of tumors. Interim Phase 2 data reported at the annual meeting of the American Society of Clinical Oncology suggest the AstraZeneca and Daiichi Sankyo drug has potential to treat many of these cancers.
-
Sanofi Reports Data Showing RSV Drug Protects Infants in Real-World Conditions
The antibody drug, nirsevimab, is designed with a long half-life intended to protect infants from respiratory syncytial virus infection through the entire season. The drug, co-developed by AstraZeneca and Sanofi, is under FDA review.
-
The Public Health Emergency Is Expiring, So What Is the Future of Covid-19 Vaccines?
The FDA will decide this summer which strains the next Covid-19 vaccines should address. But companies are also taking a longer view, developing shots for the future that offer different features than the current ones and potentially broader protection against a wider range of pathogens.
-
Roche Drug for Rare Blood Disorder Hits Phase 3 Goals; Regulatory Filings Are Next
AstraZeneca dominates the market for drugs that treat rare blood disorder paroxysmal nocturnal hemoglobinuria. Roche drug crovalimab met the two main goals of its pivotal test, and if approved, would offer a dosing edge compared to AstraZeneca’s two blockbuster PNH medicines.
-
Devices & Diagnostics, Pharma, BioPharma
AstraZeneca, Avillion Land FDA Approval for First of Its Kind Asthma Inhaler
The FDA approved Airsupra, an asthma rescue inhaler that administers two different medications, one that opens up airways and another that treats inflammation. The inhaler stems from a partnership between AstraZeneca and Avillion.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
A VC’s take on the $1.3 billion acquisition of CinCor Pharma by AstraZeneca
Maina Bhaman, a board member of CinCor Pharma reflects on the news from Monday that AstraZeneca is acquiring the Massachusetts startup to bring another option for patients with resistant hypertension.
-
M&A Monday: AstraZeneca Leads Way as 3 Pharmas Splash Out $3.5B in Deals
AstraZeneca has committed $1.3 billion to acquire CinCor Pharma, a clinical-stage biotech whose lead drug candidate has the potential to treat hypertension in a new way. In other M&A news, Ipsen and Chiesi Farmaceutici each announced acquisitions of rare disease biotechs. All three deals come with contingent value rights.
-
Novartis Tops AstraZeneca With Blood Drug Data at ASH; FDA Is Next Stop
Nearly all patients treated with the Novartis drug iptacopan achieved the hemoglobin goals of a pivotal study compared to zero patients who received the AstraZeneca drugs that are the standard of care in a rare blood disorder. The results were presented Tuesday during the annual meeting of the American Society of Hematology.
-
AstraZeneca Puts Up $200M in Solid Bet on Startup’s Take on Cancer Cell Therapy
AstraZeneca is jumping into the chase for cell therapies that address solid tumors by acquiring Neogene Therapeutics. The startup’s technology can be used to discover and develop novel targets that may be able to broaden the scope of cell therapies for cancer.
-
AstraZeneca Drug Combo Lands FDA Nod for Non-Small Cell Lung Cancer
FDA approval of AstraZeneca’s Imjudo comes less than three weeks after the antibody won its first approval in liver cancer. Both regulatory decisions cover use of the drug in combination with another AstraZeneca immunotherapy, Imfinzi.
-
AstraZeneca & Sanofi Win European Nod for RSV-Preventing Drug for Infants
AstraZeneca already has a respiratory syncytial virus antibody drug on the market for premature babies. But the approval of Beyfortus, which was developed with Sanofi, covers all infants broadly and it protects during the entire RSV season with just a single shot.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
